



**[Updated]**

05 Nov 2020

Dear Healthcare Professionals,

**Subject: Safety Information Update on Otsuka Pharmaceutical Products**

At Otsuka, patient safety is our utmost priority. As such, we endeavor to provide the latest prescribing information to the local medical community to assist in the best practice and to foster safe use of medicines.

We would like to inform you that we have been recently granted the regulatory approval for the upcoming version of the package insert of the following products, which contains updated safety information:

**Product name: JINARC TABLETS 30MG (HK-65098)**  
**JINARC TABLETS 90MG + 30MG (HK-65099)**  
**JINARC TABLETS 45MG + 15MG (HK-65100)**  
**JINARC TABLETS 15MG (HK-65101)**  
**JINARC TABLETS 60MG + 30MG (HK-65102)**

**Version Date: 05/2020**

**Product name: Rexulti Tablets 0.25 mg (HK-66303)**  
**Rexulti Tablets 0.5 mg (HK-66304)**  
**Rexulti Tablets 1 mg (HK-66305)**  
**Rexulti Tablets 2 mg (HK-66306)**  
**Rexulti Tablets 3 mg (HK-66307)**  
**Rexulti Tablets 4 mg (HK-66308)**

**Version Date: August 2020**

If you are interested in knowing further about these safety information changes prior to the print of the package insert in the sales pack, please do not hesitate to contact our Medical (PV) Department.

Thank you for your attention and your continued support of Otsuka products.

*Disclaimer: This Dear HCP Letter is meant for communicating to the medical practitioner about the upcoming safety changes to be appeared in the package insert of Otsuka products concerned. Its sole purpose is to facilitate scientific, non-promotional communication.*



Yours sincerely,  
Medical (PV) Department  
Otsuka Pharmaceutical (H.K.) Limited

*Disclaimer: This Dear HCP Letter is meant for communicating to the medical practitioner about the upcoming safety changes to be appeared in the package insert of Otsuka products concerned. Its sole purpose is to facilitate scientific, non-promotional communication.*